[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 13 of about 13
1. Campagne G, Roca M, Martínez A: Successful treatment of a high-grade intraepithelial neoplasia with imiquimod, with vulvar pemphigus as a side effect. Eur J Obstet Gynecol Reprod Biol; 2003 Aug 15;109(2):224-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of a high-grade intraepithelial neoplasia with imiquimod, with vulvar pemphigus as a side effect.
  • Imiquimod modulates the immune response, and is a new approach for treatment of papillomavirus-associated lesions, although it has not been approved for the treatment of intraepithelial neoplasia.
  • We present a case of a patient treated with imiquimod on account of high-grade intraepithelial neoplasia in the vulva and other locations.
  • The posterior biopsies confirm the absence of lesions but show drug-induced pemphigus as a side effect.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / therapy. Genital Neoplasms, Female / therapy. Pemphigus / chemically induced. Vulvar Diseases / chemically induced
  • [MeSH-minor] Adult. Carcinoma in Situ / diagnosis. Carcinoma in Situ / therapy. Carcinoma in Situ / virology. Female. Humans. Papillomaviridae / drug effects. Papillomavirus Infections / chemically induced. Treatment Outcome. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / therapy. Uterine Cervical Neoplasms / virology. Vaginal Neoplasms / diagnosis. Vaginal Neoplasms / therapy. Vaginal Neoplasms / virology. Vulvar Neoplasms / diagnosis. Vulvar Neoplasms / therapy. Vulvar Neoplasms / virology

  • Genetic Alliance. consumer health - Pemphigus.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Pemphigus.
  • MedlinePlus Health Information. consumer health - Vulvar Disorders.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Obstet Gynecol Reprod Biol. 2004 Aug 10;115(2):242-3 [15262368.001]
  • (PMID = 12860347.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


2. Sewaki T: [Generation of mucosal vaccine utilizing lactobacillus display system]. Yakugaku Zasshi; 2009 Nov;129(11):1327-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have developed novel surface display system based on PgsA gene, which isolated from Bacillus subtilis chungkookjang.
  • HPV oncogene, E7, is a reliable target protein since E7 is expressed in the CIN lesion.
  • There is no therapeutic vaccine utilizing oral administration and there is no clinical trial which addresses cervical mucosal cellular immune responses to the vaccine.
  • Our recent progress is production of a mucosal vaccine to treat cervical intraepithelial neoplasia (CIN) that has potential of cervical cancer.
  • The vaccine is expected to help the vast number of women suffering from high grade CIN.
  • Lac-E7 is a candidate for new therapeutic vaccine for cervical intraepithelial neoplasia.
  • [MeSH-major] Cancer Vaccines. Drug Design. Genetic Engineering / methods. Lactobacillus. Papillomavirus Vaccines
  • [MeSH-minor] Antigen Presentation. Cervical Intraepithelial Neoplasia / therapy. Cervical Intraepithelial Neoplasia / virology. Female. Humans. Oncogene Proteins, Viral. Papillomavirus E7 Proteins

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19881204.001).
  • [ISSN] 0031-6903
  • [Journal-full-title] Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
  • [ISO-abbreviation] Yakugaku Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Oncogene Proteins, Viral; 0 / Papillomavirus E7 Proteins; 0 / Papillomavirus Vaccines; 0 / oncogene protein E7, Human papillomavirus type 16
  • [Number-of-references] 29
  •  go-up   go-down


3. Stanley MA: Prognostic factors and new therapeutic approaches to cervical cancer. Virus Res; 2002 Nov;89(2):241-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors and new therapeutic approaches to cervical cancer.
  • Recent advances in the detection and therapy of carcinoma of the cervix and its squamous intra-epithelial precursor lesions exploit the knowledge that these lesions are a consequence of infection with high risk (HR) human papillomavirus (HPV).
  • HPV infections over-ride cell cycle controls and antibody based immunodetection of proteins that regulate DNA replication may facilitate mass automated cervical smear screening.
  • Detection of HR HPV DNA in smears from selected patient groups will improve detection of high grade precursor lesions and immunodetection of the cell cycle dependent kinase inhibitor p16(INK4a) seems to specifically and sensitively identify HGSIL.
  • Immunisation with HPV early proteins has been shown to have both prophylactic and therapeutic efficacy in animal papillomavirus infections and immunotherapies for low grade intra-epithelial lesions are realistic.
  • Immunotherapies for HPV associated high grade pre-cancers and invasive cancers are problematic in view of tumour immune evasion.
  • [MeSH-major] Antiviral Agents / therapeutic use. Papillomaviridae / immunology. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / drug therapy. Viral Vaccines / therapeutic use
  • [MeSH-minor] Cervical Intraepithelial Neoplasia / diagnosis. Cervical Intraepithelial Neoplasia / drug therapy. Cervical Intraepithelial Neoplasia / virology. Female. Genes, p16. Humans. Papillomavirus Infections / drug therapy. Prognosis. Tumor Virus Infections / drug therapy


Advertisement
4. Bulten J, de Wilde PC, Boonstra H, Gemmink JH, Hanselaar AG: Proliferation in "atypical" atrophic pap smears. Gynecol Oncol; 2000 Nov;79(2):225-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Atrophic cervical epithelium of postmenopausal women may mimic high-grade cervical intraepithelial neoplasia (CIN2-3) in Papanicolaou-stained cervical smears (Pap smears).
  • The aim of this study was to determine whether measurement of proliferative activity in Pap smears of postmenopausal patients that were difficult to interpret is a reliable test for differentiating between cervical atrophy and high-grade CIN.
  • METHODS: Pap smears obtained before and after estrogen treatment of 30 postmenopausal women with an atypical Pap smear were restained with the monoclonal antibody MIB1 to visualize proliferating cells.
  • The proliferative activity index (PAI) was subsequently measured in order to explore the feasibility of a recently proposed PAI-based diagnostic decision tree to reduce the number of estrogen courses and follow-up Pap smears in postmenopausal women.
  • RESULTS: The PAI-based test to discriminate between cervical atrophy and high-grade CIN resulted in 100 and 96% correct diagnoses in women with high-grade CIN and cervical atrophy, respectively.
  • Only 2 of the 30 women would have needed a repeated Pap smear after estrogen treatment for definite diagnosis if the PAI-based diagnostic decision had been used.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / pathology. Cervix Uteri / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Antibodies, Monoclonal. Atrophy / drug therapy. Atrophy / pathology. Cell Division / drug effects. Decision Trees. Diagnosis, Differential. Epithelium / drug effects. Epithelium / pathology. Estriol / therapeutic use. Female. Humans. Immunohistochemistry. Ki-67 Antigen / immunology. Postmenopause / physiology. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. ESTRIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Academic Press.
  • (PMID = 11063649.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Ki-67 Antigen; FB33469R8E / Estriol
  •  go-up   go-down


5. González Sánchez JL, Flores Murrieta G, Chávez Brambila J, Deolarte Manzano JM, Andrade Manzano AF: [Topical 5-fluorouracil for treatment of vaginal intraepithelial neoplasms]. Ginecol Obstet Mex; 2002 May;70:244-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Topical 5-fluorouracil for treatment of vaginal intraepithelial neoplasms].
  • [Transliterated title] 5-fluorouracilo tópico en el tratamiento de la neoplasia intraepitelial vaginal.
  • OBJECTIVE: Our purpose was to determine the effectiveness of 5-fluorouracil (5-FU) in the treatment of vaginal intraepithelial neoplasia (VAIN).
  • Patients received intravaginal treatment with 5-FU, 1.5 g once weekly for 10 weeks and all patients were followed up for at least 2-years.
  • RESULTS: Twenty eight (93%) patients with VAIN had prior or concurrent anogenital squamous neoplasia, including 5 with invasive cervical carcinoma and 23 with cervical intraepithelial neoplasia.
  • In 23 of 30 treated patients (77%), VAIN went into remission after a single treatment; in 3, (10%), it went into remission after two treatment; 3 (10%) had recurrent VAIN 3; and in 1 (3%) it progressed to invasive vaginal cancer.
  • The treatment was well tolerated.
  • CONCLUSIONS: The 5-FU is an option choice for VAIN treatment.
  • Its use should be confined to treating extensive or multifocal high-grade VAIN.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Cervical Intraepithelial Neoplasia / drug therapy. Fluorouracil / therapeutic use. Vaginal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Papanicolaou Test. Papilloma / drug therapy. Papilloma / pathology. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / pathology. Vaginal Smears

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12148464.001).
  • [ISSN] 0300-9041
  • [Journal-full-title] Ginecología y obstetricia de México
  • [ISO-abbreviation] Ginecol Obstet Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; U3P01618RT / Fluorouracil
  •  go-up   go-down


6. Kiatpongsan S, Niruthisard S, Mutirangura A, Trivijitsilp P, Vasuratna A, Chaithongwongwatthana S, Lertkhachonsuk R: Role of human papillomavirus DNA testing in management of women with atypical squamous cells of undetermined significance. Int J Gynecol Cancer; 2006 Jan-Feb;16(1):262-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of human papillomavirus DNA testing in management of women with atypical squamous cells of undetermined significance.
  • To find the sensitivity, specificity, and positive and negative predictive values of the high-risk group human papillomavirus (HPV) DNA testing as a triage tool to detect high-grade squamous intraepithelial lesions (HSILs, ie, cervical intraepithelial neoplasia [CIN] 2 or worse) in women with a cytologic smear showing atypical squamous cells of undetermined significance (ASC-US).
  • Cervical cell samplings were done by cervical cytobrush technique and tested for high-risk group HPV with the Hybrid Capture 2 (HC2) test.
  • Then cervicographs were taken before colposcopic-directed cervical biopsies were done.
  • Of the 90 ASC-US cases enrolled, the pathologic results were normal in 30.0%, squamous metaplasia in 16.7%, CIN 1 in 37.8%, CIN 2 in 1.1%, CIN 3 in 11.1%, and microinvasive cervical carcinoma in 3.3%.
  • The prevalence of HSILs and the prevalence of high-risk HPV detection were 15.6% and 38.9%, respectively.
  • Using pathologic results from cervical biopsy as the gold standard, the HC2 has the sensitivity, specificity, and positive and negative predictive values of 85.7%, 69.7%, 34.3%, and 96.4%, respectively, to detect HSILs.
  • High-risk group HPV detection can be used as an additional triage test to detect HSILs in women having ASC-US with high sensitivity and negative predictive value.
  • [MeSH-major] Carcinoma, Squamous Cell / virology. Cervical Intraepithelial Neoplasia / virology. DNA, Viral / analysis. Papillomaviridae / isolation & purification. Uterine Cervical Neoplasms / virology
  • [MeSH-minor] Adolescent. Adult. Biopsy, Needle. Cohort Studies. DNA Probes, HPV. Female. Humans. Immunohistochemistry. Middle Aged. Papillomavirus Infections / diagnosis. Papillomavirus Infections / drug therapy. Risk Assessment. Sensitivity and Specificity. Thailand. Triage


7. Ayas S, Karateke A, Aköz I, Kir G, Yenidede I: Primary serous carcinoma of the fallopian tube with synchronous cervical epidermoid carcinoma in situ: a case report. Eur J Gynaecol Oncol; 2007;28(6):501-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary serous carcinoma of the fallopian tube with synchronous cervical epidermoid carcinoma in situ: a case report.
  • In this report we present a rare case of primary carcinoma of the fallopian tube with synchronous cervical high-grade squamous intraepithelial lesion (HSIL).
  • A 39-year-old women was admitted to our hospital for routine gynecological examination and underwent surgery because of the finding of HSIL on a routine papanicolaou smear.
  • The histological diagnosis on cervical biopsy and conization material were of cervical intraepithelial neoplasia III (CIN III).
  • Postoperatively the patient received six cycles of adjuvant chemotherapy (carboplatin and paclitaxel) and is still under routine control.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Fallopian Tube Neoplasms / diagnosis. Uterine Cervical Neoplasms / diagnosis


8. Trimble C, Lin CT, Hung CF, Pai S, Juang J, He L, Gillison M, Pardoll D, Wu L, Wu TC: Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine; 2003 Sep 8;21(25-26):4036-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have previously linked Mycobacterium tuberculosis heat shock protein 70 (HSP70) to human papillomavirus type 16 (HPV-16) E7 in the context of a DNA vaccine.
  • The success of our strategy has led to two phases I/II clinical trial proposals in patients with HPV-16 associated high-grade squamous intraepithelial lesion (HSIL) of the cervix and in patients with advanced HPV-associated head and neck squamous cell carcinoma (HNSCC).
  • [MeSH-minor] Animals. Antibody Specificity. Biolistics. Cytokines / biosynthesis. Female. Flow Cytometry. HSP70 Heat-Shock Proteins / immunology. Injections, Intramuscular. Interferon-gamma / biosynthesis. Mice. Mice, Inbred C57BL. Papilloma / drug therapy. Papilloma / pathology. Papilloma / prevention & control. Papillomaviridae / immunology. Plasmids / genetics. Vaccines, DNA / administration & dosage. Vaccines, DNA / immunology

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12922140.001).
  • [ISSN] 0264-410X
  • [Journal-full-title] Vaccine
  • [ISO-abbreviation] Vaccine
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Cytokines; 0 / HSP70 Heat-Shock Proteins; 0 / Vaccines, DNA; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


9. Feng W, Duan X, Liu J, Xiao J, Brown RE: Morphoproteomic evidence of constitutively activated and overexpressed mTOR pathway in cervical squamous carcinoma and high grade squamous intraepithelial lesions. Int J Clin Exp Pathol; 2009;2(3):249-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphoproteomic evidence of constitutively activated and overexpressed mTOR pathway in cervical squamous carcinoma and high grade squamous intraepithelial lesions.
  • Human papilloma virus (HPV) infection of the uterine cervix is linked to the pathogenesis of cervical cancer.
  • Preclinical in vitro and in vivo studies using HPV-containing human cervical carcinoma cell lines have shown that the mammalian target of rapamycin (mTOR) inhibitor, rapamycin, and epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, erlotinib, can induce growth delay of xenografts.
  • Activation of Akt and mTOR are also observed in cervical squamous cell carcinoma and, the expression of phosphorylated mTOR was reported to serve as a marker to predict response to chemotherapy and survival of cervical cancer patients.
  • Therefore, we investigated: a) the expression level of EGFR in cervical squamous cell carcinoma (SCC) and high-grade squamous intraepithelial lesions (HSIL) versus non-neoplastic cervical squamous epithelium;.
  • b) the state of activation of the mTOR pathway in these same tissues; and c) any impact of these signal transduction molecules on cell cycle.
  • Formalin-fixed paraffin-embedded tissue microarray blocks containing 20 samples each of normal cervix, HSIL and invasive SCC, derived from a total of 60 cases of cervical biopsies and cervical conizations were examined.
  • We found that plasmalemmal EGFR expression was limited to the basal/parabasal cells (2-3+, EI = 67) in normal cervical epithelium (NL), but was diffusely positive in all HSIL (EI = 237) and SCC (EI 226).
  • The pattern of cytoplasmic p-mTOR and nuclear p-p70S6K expression was similar to that of EGFR; all showed a significantly increased EI in HSIL/SCC versus NL (p<0.02).
  • Nuclear translocation of p-mTOR was observed in all SCC lesions (EI = 202) and was significantly increased versus both HSIL (EI = 89) and NL (EI = 54) with p<0.015 and p<0.0001, respectively.
  • Concomitant increases in MI and proportion of nuclear Ki-67 and Skp2 expression were noted in HSIL and SCC.
  • In conclusion, morphoproteomic analysis reveals constitutive activation and overexpression of the mTOR pathway in HSIL and SCC as evidenced by: increased nuclear translocation of pmTOR and p-p70S6K, phosphorylated at putative sites of activation, Ser2448 and Thr389, respectively; correlative overexpression of the upstream signal transducer, EGFR, and increases in cell cycle correlates, Skp2 and mitotic indices.
  • These results suggest that the mTOR pathway plays a key role in cervical carcinogenesis and targeted therapies may be developed for SCC as well as its precursor lesion, HSIL.


10. Buxant F, Bucella D, Anaf V, Simon P, Noël JC: Glucocorticoid receptor expression in cervical intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix. Eur J Gynaecol Oncol; 2009;30(3):259-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glucocorticoid receptor expression in cervical intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix.
  • OBJECTIVES: Glucocorticoids (GCs) are used in cancer treatment to cause programmed cell death in transformed cells of the hematopoietic system and to lessen side-effects as nausea, vomiting, edema formation and allergies to specific chemotherapeutic agents.
  • GCs act also as cofactor with human papillomaviruses in the etiology of cervical cancer.
  • Moreover, recently GCs were described as inhibitors of some chemotherapy or radiation-induced apoptosis.
  • METHODS: To clarify the issue, we tested by immunohistochemistry the expression status of GR in normal cervix epithelium (n = 30), in low-grade cervical intraepithelial neoplasia (LSIL) (n = 30), in high-grade cervical intraepithelial neoplasia (HSIL) (n = 30) and in invasive squamous cell carcinoma (ISCC) (n = 30).
  • All the patients with these lesions have a corresponding liquid-based cytology and were proved to be HPV-positive by using hybrid capture 2 methodology with probes against high-risk oncogenic HPvs. The evaluation of GR expression was performed by using the H-score system and an H-score > 50 was considered positive.
  • RESULT: GR expression was observed in normal epithelium, LSIL, HSIL and ISCC.
  • CONCLUSION: Because GCs could play a positive role in the progression of cancer, our demonstration of GR persistence in cervix cancer cells raises concern about the widespread combined use of GCs with antineoplastic drugs or agents in the clinical management of cervix cancer in women.
  • [MeSH-major] Carcinoma, Squamous Cell / metabolism. Cervical Intraepithelial Neoplasia / metabolism. Receptors, Glucocorticoid / metabolism. Uterine Cervical Neoplasms / metabolism


11. Sharma A, Rajappa M, Saxena A, Sharma M: Telomerase activity as a tumor marker in Indian women with cervical intraepithelial neoplasia and cervical cancer. Mol Diagn Ther; 2007;11(3):193-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Telomerase activity as a tumor marker in Indian women with cervical intraepithelial neoplasia and cervical cancer.
  • BACKGROUND AND OBJECTIVES: Cervical cancer is the most common cancer in Indian women and is a leading cause of death in women worldwide.
  • Cervical cancer develops from pre-neoplastic cervical intraepithelial neoplasia (CIN).
  • This study was conducted to evaluate telomerase activity as a tumor marker for the detection of cancer in patients with CIN and cervical cancer.
  • METHODS: Telomerase activity was detected using the PCR-based telomeric repeat amplification protocol (TRAP) assay in cervical tissues collected by routine punch biopsy from the uterine cervix of patients with suspected cervical cancer.
  • High-risk (HR) HPV-16 and -18 status was determined in all the study groups, including controls.
  • A total of 125 patients (including 50 patients with CIN and 75 patients with cervical cancer [including nine patients with adeno-squamous disease]) and 22 control subjects were studied.
  • The sensitivity and specificity for detecting CIN and cervical cancer were calculated.
  • RESULTS: Patients with grade I, II, and III CIN showed 17%, 33%, and 57% positivity for telomerase, respectively.
  • In patients with cervical cancer, those at early clinical stages (Ia-IIb) showed 68% positivity and those at later clinical stages showed 92% positivity for telomerase activity.
  • In the present study, telomerase positivity correlated significantly with the detection of HR HPV-16 and -18 (p < 0.001).
  • CONCLUSION: Our findings suggest that telomerase activation is a relatively early event in cervical carcinogenesis and correlates with the grade of cervical lesion, HR-HPV status (16 and 18 subtypes), and clinical staging.
  • Hence, these associations suggest it as a possible target for detection of cervical cancer.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / enzymology. Human papillomavirus 16 / metabolism. Human papillomavirus 18 / metabolism. Papillomavirus Infections / complications. Telomerase / metabolism. Uterine Cervical Neoplasms / enzymology

  • Genetic Alliance. consumer health - Cervical Intraepithelial Neoplasia.
  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gen Virol. 1992 Dec;73 ( Pt 12):3263-8 [1335027.001]
  • [Cites] J Clin Microbiol. 1990 Mar;28(3):495-503 [1691208.001]
  • [Cites] APMIS. 2001 Sep;109(9):607-17 [11878714.001]
  • [Cites] Oncogene. 1998 Apr 30;16(17):2243-8 [9619833.001]
  • [Cites] Int J Cancer. 1998 Feb 20;79(1):66-70 [9495361.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11549-54 [9751703.001]
  • [Cites] J Virol Methods. 1993 May;42(2-3):265-79 [8390474.001]
  • [Cites] FASEB J. 1998 Jul;12(10):801-11 [9657520.001]
  • [Cites] J Clin Pathol. 2003 Jan;56(1):31-5 [12499429.001]
  • [Cites] Chin Med J (Engl). 2004 Feb;117(2):202-6 [14975203.001]
  • [Cites] Hum Pathol. 2000 Oct;31(10):1304-12 [11070123.001]
  • [Cites] Int J Gynecol Cancer. 2001 Mar-Apr;11(2):100-6 [11328407.001]
  • [Cites] Clin Obstet Gynecol. 2000 Jun;43(2):352-62 [10863633.001]
  • [Cites] Nature. 1991 Apr 18;350(6319):569-73 [1708110.001]
  • [Cites] Drug Resist Updat. 1999 Apr;2(2):104-115 [11504478.001]
  • [Cites] Int J Cancer. 2001 Mar 1;91(5):658-64 [11267977.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1932-7 [9164204.001]
  • [Cites] Clin Lab Med. 2000 Jun;20(2):369-82 [10863645.001]
  • [Cites] Science. 1994 Dec 23;266(5193):2011-5 [7605428.001]
  • [Cites] Gynecol Oncol. 1997 Aug;66(2):222-6 [9264566.001]
  • [Cites] Oncogene. 2002 Jan 21;21(4):664-73 [11850794.001]
  • [Cites] In Vivo. 2001 Jul-Aug;15(4):327-32 [11695225.001]
  • [Cites] Hum Pathol. 2004 Apr;35(4):396-402 [15116318.001]
  • [Cites] Eur J Cancer. 1999 Jan;35(1):154-60 [10211104.001]
  • [Cites] Clin Chem Lab Med. 2002 Oct;40(10):994-1001 [12476937.001]
  • [Cites] Clin Cancer Res. 1996 Dec;2(12):2023-8 [9816162.001]
  • [Cites] Int J Cancer. 1993 Dec 2;55(6):891-903 [8253525.001]
  • [Cites] Gynecol Oncol. 1997 Jan;64(1):171-5 [8995569.001]
  • [Cites] J Natl Cancer Inst Monogr. 1996;(21):1-6 [9023822.001]
  • [Cites] Eur J Cancer. 2000 Nov;36(17):2215-20 [11072207.001]
  • [Cites] Nat Biotechnol. 1996 May;14(5):615-9 [9630953.001]
  • [Cites] J Low Genit Tract Dis. 2005 Apr;9(2):93-9 [15870530.001]
  • [Cites] Obstet Gynecol. 1998 Feb;91(2):260-2 [9469286.001]
  • [Cites] J Clin Pathol. 2005 Sep;58(9):911-4 [16126869.001]
  • [Cites] Exp Biol Med (Maywood). 2005 Apr;230(4):263-70 [15792948.001]
  • [Cites] Oncol Res. 1995;7(3-4):121-30 [8555645.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] Gynecol Oncol. 2004 Jan;92(1):15-21 [14751132.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1319-27 [9529024.001]
  • [Cites] Gynecol Oncol. 2000 Jun;77(3):394-8 [10831348.001]
  • (PMID = 17570741.001).
  • [ISSN] 1177-1062
  • [Journal-full-title] Molecular diagnosis & therapy
  • [ISO-abbreviation] Mol Diagn Ther
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] New Zealand
  • [Chemical-registry-number] EC 2.7.7.49 / Telomerase
  •  go-up   go-down


12. Atkins KA, Jeronimo J, Stoler MH, ALTS Group: Description of patients with squamous cell carcinoma in the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion triage study. Cancer; 2006 Aug 25;108(4):212-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Description of patients with squamous cell carcinoma in the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion triage study.
  • BACKGROUND: The Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS) accumulated information regarding conventional and liquid-based Papanicolaou (Pap) cytology, 2 kinds of human papillomavirus (HPV) DNA testing, cervicography, and colposcopically directed biopsy.
  • The prevalence of squamous cell carcinoma in these women, the efficacy of tests, and the time to detection were reviewed.
  • All results of colposcopy, HPV testing, cytology, biopsies, and cervigrams were reviewed for all women in the ALTS trial who were diagnosed with squamous cell carcinoma.
  • RESULTS: There were 7 diagnoses of invasive cancer (all squamous cell) during the 2 years of the ALTS trial.
  • Although the enrollment studies isolated many high-grade lesions, none of those results were diagnostic of the underlying carcinoma.
  • CONCLUSIONS: The prevalence of squamous cell carcinoma in the setting of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion cytology interpretation appears to be low (approximately 1 per 1000 women in the ALTS trial).
  • Type-specific testing identified HPV type 16 in 6 of 7 cancers and HPV type 18 in 1 of 7 cancers.
  • [MeSH-major] Carcinoma in Situ / diagnosis. Carcinoma, Squamous Cell / diagnosis. Cervical Intraepithelial Neoplasia / diagnosis. Papillomavirus Infections / diagnosis. Uterine Cervical Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16680733.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CN / CN-55105; United States / NCI NIH HHS / CN / CN-55152; United States / NCI NIH HHS / CN / CN-55154; United States / NCI NIH HHS / CN / CN-55155; United States / NCI NIH HHS / CN / CN-55156; United States / NCI NIH HHS / CN / CN-55157; United States / NCI NIH HHS / CN / CN-55158; United States / NCI NIH HHS / CN / CN-55159
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


13. Caprara L, Monari F, De Bianchi PS, Amadori A, Bondi A: [ASCUS in screening]. Pathologica; 2001 Dec;93(6):645-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The significance and use of the cytological diagnosis "atypical squamous cells of undetermined significance" (ASCUS) remain a major problem in cervical cancer screening.
  • The prevalence of diagnoses of low-grade squamous intraepithelial lesions (LG-SIL) decreased progressively with age while that of high-grade SIL was slightly higher between 30 and 39 years.
  • The observed peak reflects the prevalence of (1) cytological changes closely associated with perimenopausal age and at least compatible with the ASCUS diagnosis, and (2) cytological abnormalities induced by hormone replacement therapy.
  • [MeSH-major] Cervix Uteri / pathology. Mass Screening. Papanicolaou Test. Vaginal Smears
  • [MeSH-minor] Adult. Aged. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Cervical Intraepithelial Neoplasia / diagnosis. Cervical Intraepithelial Neoplasia / pathology. Epithelial Cells / drug effects. Epithelial Cells / ultrastructure. Estrogens / pharmacology. False Positive Reactions. Female. Hormone Replacement Therapy. Humans. Italy. Menopause. Middle Aged. Neoplastic Stem Cells / ultrastructure. Progesterone / pharmacology. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / pathology






Advertisement